Previous 10 | Next 10 |
2023-11-14 12:17:09 ET PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript November 14, 2023 08:00 AM ET Company Participants Nicole Jones - Investor Relations Frank Bedu-Addo - Chief Executive Officer Matthew Hill - Chief Financial Officer ...
2023-11-14 07:37:02 ET More on PDS Biotechnology PDS Biotechnology: PDS0101 Being Put To The Test PDS Biotech reports encouraging survival data for HPV 16+ cancer therapy PDS Biotech posts Phase 1/2 data for prostate cancer therapy Seeking Alpha’s Quan...
Announced 75% of ICI-naive patients alive at 36 months in the NCI-led triple Phase 2 combination trial for advanced HPV16-positive cancer patients; published median overall survival of 7-11 months with FDA approved ICI 1 Announced 2-year overall survival rate of 74% in VERSATILE-0...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
PDS Biotechnology Corporation (PDSB) is expected to report $-0.42 for Q3 2023
2023-11-13 13:09:25 ET More on PDS Biotechnology PDS Biotechnology: PDS0101 Being Put To The Test PDS Biotech reports encouraging survival data for HPV 16+ cancer therapy PDS Biotech posts Phase 1/2 data for prostate cancer therapy Seeking Alpha’s Quan...
2023-11-13 09:41:06 ET Major earnings expected before the bell on Tuesday include: Canadian Solar ( CSIQ ) The Home Depot ( HD ) Sea ( SE ) Vodafone Group Public ( VOD ) Workhorse Group ( WKHS ) For further details see: Notable earnings be...
2023-11-09 10:40:49 ET More on PDS Biotechnology PDS Biotechnology: PDS0101 Being Put To The Test PDS Biotechnology (PDSB) Q2 2023 Earnings Call Transcript PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study PDS Biotech posts Phase 1/2 data ...
75% of immune checkpoint inhibitor (ICI) naïve patients remain alive at 36 months; published median overall survival (OS) in similar patients is 7-11 months 12-month survival rate in ICI resistant patients is 72% Median OS in ICI resistant patients is approximately 20 months;...
PRINCETON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s propr...
News, Short Squeeze, Breakout and More Instantly...
PDS Biotechnology Corporation Company Name:
PDSB Stock Symbol:
NYSE Market:
PDS Biotechnology Corporation Website:
PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage imm...
PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious...
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious...